SKF 86002

SKF 86002 is an anti-inflammatory agent.^1,2,3,4 It inhibits rat seminal vesicle prostaglandin H₂ (PGH₂) synthase (IC₅₀ = 120 µM), as well as prostanoid production by rat basophilic leukemia (RBL-1) cells and human monocytes (IC₅₀s = 70 and 1 µM, respectively).¹ SKF 86002 inhibits leukotriene B₄ (LTB₄) and LTC₄ production induced by A23187 (Item No. 11016) in human neutrophils and monocytes, respectively (IC₅₀ = 20 µM for both). It also inhibits LPS-induced IL-1 production in human monocytes (IC₅₀ = 1.3 µM).² SKF 86002 (10, 30, and 90 mg/kg) reduces hindleg volume in rat models of adjuvant- or collagen-induced arthritis.³ It also decreases serum levels of TNF-α and increases survival in a mouse model of LPS and galactosamine-induced endotoxic shock when administered at a dose of 100 mg/kg.⁴

WARNING This product is not for human or veterinary use.

1. Griswold, D.E., Marshall, P.J., Webb, E.F., et al. SK&F 86002: A structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem. Pharmacol. 36(20), 3463-3470 (1987).

2. Lee, J.C., Griswold, D.E., Votta, B., et al. Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002. Int. J. Immunopharmacol. 10(7), 835-843 (1988).

3. DiMartino, M.J., Griswold, D.E., Berkowitz, B.A., et al. Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase. Agents Actions 20(1-2), 113-123 (1987).

4. Badger, A.M., Olivera, D., Talmadge, J.E., et al. Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: Inhibition of tumor necrosis factor as a possible mechanism of action. Circ. Shock 27(1), 51-61 (1989).